Vivoryon Therapeutics AG (GB:0R3M) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Vivoryon Therapeutics N.V. is set to present its findings on Varoglutamstat, a potential new treatment for Diabetic Kidney Disease, at ASN Kidney Week 2024. The clinical-stage biotechnology company is exploring Varoglutamstat’s ability to increase glomerular filtration in the elderly without proteinuria. Vivoryon, known for its work on small molecule medicines, continues to expand its pipeline with treatments for Alzheimer’s, kidney diseases, cancer, and more.
For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.